There are 2867 resources available
Introduction
Presenter: Christoph Benedikt Westphalen
Session: Complex technologies for diagnosis: How do we implement and use them globally?
Resources:
Slides
Webcast
Update on diagnosis: Novel concepts of WHO
Presenter: Pieter Wesseling
Session: Insight the new CNS WHO classification: Novel concepts and therapeutic implications for gliomas
Resources:
Slides
Webcast
Introduction and scientific background
Presenter: Angela Lamarca
Session: Lessons learned and new horizons and other hepatobiliary/pancreatic malignancies
Resources:
Slides
Webcast
Introduction and scientific background
Presenter: Jarushka Naidoo
Session: Slicing the pie: Advances in targeted therapy for oncogene-addicted NSCLC
Resources:
Slides
Webcast
Introduction and scientific background
Presenter: Caroline Robert
Session: Is heterogeneity the limitation of precision oncology in melanoma?
Resources:
Slides
Webcast
Introduction
Presenter: Hendrik van Halteren
Session: De-escalation of treatment in medical oncology
Resources:
Slides
Webcast
LBA67 - Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial
Presenter: Mohamad Allaf
Session: Proffered Paper session 1: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
LBA13 - Nivolumab and ipilimumab in early-stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): First results from the BELLINI trial
Presenter: Marleen Kok
Session: Proffered Paper session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
452O - A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2–p53 antagonist BI 907828 in patients (pts) with solid tumours
Presenter: Patrick Schoeffski
Session: Proffered Paper session: Developmental therapeutics
Resources:
Abstract
Slides
Webcast
1483O - Results of a phase I/II combination regimen with ipilimumab (I), nivolumab (N) and trabectedin (T) as first line therapy for advanced leiomyosarcoma
Presenter: Erlinda Gordon
Session: Proffered Paper session: Sarcoma
Resources:
Abstract
Slides
Webcast